Non-Clinical Solutions
The burden of cardiovascular disease extends beyond the clinical setting. It impacts every major healthcare stakeholder.
Building on insights from our clinical solutions, HeartRisk integrates and aggregates multiple data sources in a HIPAA compliant manner. This data intelligence platform drives value by delivering critical and custom insights to stakeholders for strategic decision-making.
|
|
|
Patients |
In the United States, heart disease is responsible for approximately 659,000 deaths, which equates to 1 in every 4 deaths, annually |
• Obtain personalized insights into heart disease • Receive more timely and targeted interventions |
Providers |
Heart disease accounts for approximately 25% of emergency room visits related to chest pain, which can strain hospital resources, particularly in emergency departments |
• Extend cardiovascular risk assessments and detection to primary care settings • Risk stratify and detect heart disease in patients via a simple blood draw and gain actionable clinical insights |
Payers |
Heart disease is responsible for a substantial portion of healthcare expenditure. In 2015, approximately 14% of total U.S. healthcare expenditure was attributed to cardiovascular disease |
• Reduce utilization by identifying plan members at risk and ensure providers can develop a personalized remediation plan • Enable plan care navigation teams to effectively partner with plan members at risk |
Employers |
Employers may face increased healthcare costs due to heart disease, as employees with cardiovascular diseases have medical costs that are twice as high as those without the condition |
• Reduce costly utilization and catastrophic claims for self-funded employers by emphasizing primary and secondary prevention • Improve employee productivity and engagement |
Government |
Heart disease is among the leading causes of death for more than 2 million individuals incarcerated in state or federal prisons across the United States |
• Implement and scale statewide population strategies tackling cardiovascular disease in corrections facilities, nursing homes, mental health institutions, and other vulnerable populations who are difficult to transport to specialty cardiology centers • Improve the ability to assess the ROI of spend committed to programs to keep populations healthy |
Life Insurers |
As the number one killer, heart disease is a leading cause of life insurance payouts |
• Improve policy pricing models with better cardiovascular risk data • Extend the life of policyholders with advanced cardiovascular insights for members |
Pharma |
The mean cost of developing a new drug ranges from $314 million to $2.8 billion |
• Accelerate drug discovery with clinical trial designs with more precise patient targeting • Conduct post-market surveillance to monitor drug safety and effectiveness |
Epigenetics-based therapies are the next evolution in cardiovascular care and treatment, offering unprecedented opportunities to target the underlying mechanisms of cardiovascular disease. CardioInnovate360 leverages AI and epigenetics to enable and accelerate the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Identify novel epigenetic and genetic biomarkers and pathways implicated in the pathogenesis of cardiovascular disease and associated co-morbidities.
1Stratify patients more effectively for clinical trials by selecting those with a higher likelihood of responding to the investigational therapy or by providing more granular outcomes.
2Develop custom post-market surveillance or companion diagnostic tests that are non-invasive and scalable.
3